R-DHAP: A good small step, but not the journey's end

References

• Velasquez W S, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [see comments]. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Velasquez W S, McLaughlin P, Tucker S, Hagemeister F B, Swan F, Rodriguez M A, et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study [see comments]. J Clin Oncol 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Rodriguez M A, Fayad L, McLaughlin P, Swan F, Sarris A, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999; 93: 3632–3636
   PubMed Web of Science ®Google Scholar
• Harting R, Venugopal P, Gregory S A, O'Brien T, Bogdanova E. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 7: 406–412
   PubMedGoogle Scholar
• Witzig T E, Geyer S M, Kurtin P J, Colgan J P, Inwards D J, Micallef I NM, et al. Salvage chemotherapy with rituximab DHAP (RDHAP) for relapsed non-Hodgkin lymphoma (NHL): a phase II trial in the North Center Cancer Treatment Group. Leuk Lymphoma, in press
   Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986–1992
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez A J, Cheson B D, Horning S J, Peterson B A, Carter W D, Varns C L, et al. Response criteria for NHL: importance of “normal” lymph node size and correlations with response rate. Ann Oncol 2000; 11: 399–408
   PubMed Web of Science ®Google Scholar
• Rohatiner A Z, Nadler L, Davies A J, Apostolidis J, Neuberg D, Matthews J, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554–2559
   PubMed Web of Science ®Google Scholar
• Zelenetz A D, Advani R H, Buadi F, Cabanillas F, Caligiuri M A, Czuczman M S, et al. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J NCCN 2006; 4: 258–310
   Google Scholar
• Vose J M, Bierman P F, Loberiza F R, Lynch J C, Bociek G R, Weisenburger D D, et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and follicular international prognostic index. Bio Blood Marrow Transplant 2008; 14: 36–42
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Böck H-P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• van Oers M HJ, Klasa R, Marcus R E, Wolf M, Kimby E, Gascoyne R D, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Blood. 2006; 108: 3295–3301
   Google Scholar